Topics Identified in FDA Briefing Document

• Comparison to other marketed ED drugs

• Representative ED patient population

• Pharmacokinetic variabilty

• Clinical relevance of 2 mg

• Efficacy in diabetics

• Discontinuations in long-term studies

• Hemodynamics

• Nitrate interaction

• Alcohol interaction

Introduction

Previous slide

Next slide

Back to first slide

View graphic version